Edward Jordan
Corporate Officer/Principal at XSPRAY PHARMA AB
Net worth: - $ as of 2024-03-30
Profile
Edward P.
Jordan is currently the Chief Commercial Officer at Xspray Pharma AB since 2023.
Prior to this, he was the Chief Commercial Officer at Humanigen, Inc. from 2020 to 2023 and Senior Vice President at DBV Technologies, Inc. from 2016 to 2020.
He also held a senior leadership position at AMAG Pharmaceuticals, Inc. Mr. Jordan has an undergraduate degree from the University of Rhode Island and an MBA from Southern New Hampshire University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
HUMANIGEN INC
0.01% | 2023-04-10 | 12,500 ( 0.01% ) | 0 $ | 2024-03-30 |
Edward Jordan active positions
| Companies | Position | Start |
|---|---|---|
| XSPRAY PHARMA AB | Corporate Officer/Principal | 2023-09-14 |
Former positions of Edward Jordan
| Companies | Position | End |
|---|---|---|
| HUMANIGEN, INC. | Corporate Officer/Principal | 2023-09-13 |
DBV Technologies, Inc.
 DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The private company is based in New York, NY. | Corporate Officer/Principal | 2020-08-23 |
| AMAG PHARMACEUTICALS, INC. | Sales & Marketing | - |
Training of Edward Jordan
| University of Rhode Island | Undergraduate Degree |
| Southern New Hampshire University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| HUMANIGEN, INC. | Health Technology |
| XSPRAY PHARMA AB | Health Technology |
| Private companies | 2 |
|---|---|
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA. | Health Technology |
DBV Technologies, Inc.
DBV Technologies, Inc. Medical/Nursing ServicesHealth Services Part of DBV Technologies SA, DBV Technologies, Inc. provides medical care services. The private company is based in New York, NY. | Health Services |
- Stock Market
- Insiders
- Edward Jordan
